Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.
Also called NCT07396337
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 320 participants
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Registry
-
NCT07396337
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07396337. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-19 (actual); primary completion 2026-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- QHRD106 Injection (Low-dose group)
- Intervention (Drug)
- QHRD106 Injection (Middle-dose group)
- Intervention (Drug)
- QHRD106 Injection (High-dose group)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Record details
- Record id
cardio:ct-nct07396337- Content hash
b7f1f62e7193d386f4cbc39e671e1846ec4f658908e7243d62a2c3a07de6c358